Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
Real-time Quote. Real-time CHI-X - 10/16 11:30:00 am
7.67 EUR   -2.79%
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate, PXL065
AQ
08/26POXEL : Half-year results
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel SA : quaterly sales release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2019 | 09:15am EDT

The company will report its revenue for Q1 2019 on 04/08/2019. Generally, the company reports sales worse than estimates. In recent months, the 4 analysts from Thomson Reuters consensus have revised their sales estimates upward.

Stocks mentioned in the article
ChangeLast1st jan.
POXEL -1.14% 7.8 Real-time Quote.55.01%
THOMSON REUTERS CORPORATION -0.80% 86.86 Delayed Quote.32.81%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
More news
Financials (EUR)
Sales 2019 40,0 M
EBIT 2019 -17,5 M
Net income 2019 -15,1 M
Finance 2019 33,4 M
Yield 2019 -
P/E ratio 2019 -13,3x
P/E ratio 2020 -5,66x
EV / Sales2019 4,27x
EV / Sales2020 7,24x
Capitalization 204 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,89  €
Spread / Highest target 115%
Spread / Average Target 91,8%
Spread / Lowest Target 73,6%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL55.01%225
GILEAD SCIENCES4.40%82 700
VERTEX PHARMACEUTICALS4.76%45 274
REGENERON PHARMACEUTICALS-18.66%33 245
WUXI APPTEC CO., LTD.64.57%20 149
GENMAB30.26%13 356